Ra Pharmaceuticals Inc (RARX) Stock News
NASDAQ:RARX - Nasdaq -
RARX Latest News, Press Relases and Analysis
Apellis on go to file U.S. application for pegcetacoplan for rare blood disorder (NASDAQ:APLS)
On the heels of its meeting with the FDA, Apellis Pharmaceuticals (NASDAQ:APLS) announced that it expects to file a marketing application in H2 seeking approval of pegcetacoplan for the treatment of p
Is RA PHARMCTL INC (RARX) Stock Outpacing Its Medical Peers This Year?
Is (RARX) Outperforming Other Medical Stocks This Year?
How Ra Pharmaceuticals (RARX) Stock Stands Out in a Strong Industry
Ra Pharmaceuticals (RARX) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
The Daily Biotech Pulse: InflaRx Begins Human Testing For COVID-induced Pneumonia, Chembio, Becton Dickinson Launch Coronavirus Tests
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs March 31) Athersys Inc (NASDAQ: ATHX...
Stocks That Hit 52-Week Highs On Wednesday
On Wednesday, 3 companies achieved new highs for the year. Points of Interest: Ra Pharmaceuticals (NASDAQ: RARX) was the largest company by market cap to set a new 52-...
Best & Worst Performing Mid Cap Stocks for March 12, 2020
VIR – VIR leads the way today as the best performing mid cap stock, closing up 10.66%.
Analysts Offer Insights on Healthcare Companies: Ra Pharmaceuticals (NASDAQ: RARX) and Arena Pharma (NASDAQ: ARNA)
Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Ra Pharmaceuticals (RARX – Research Report) and Arena Pharma (ARNA – Research Report). Ra Pharmaceuticals (RARX) Credit Suisse analyst Spiro M. Dounis maintained a Hold rating on Ra Pharmaceuticals on March 6 and set a price target of
Mentions: ARNA
Ra Pharmaceuticals Supports 13th Annual Rare Disease Day® and Joins Global Movement to Raise Awareness for Rare Diseases
Ra Pharmaceuticals EPS misses by $0.16
Ra Pharmaceuticals (NASDAQ:RARX): Q4 GAAP EPS of -$0.79 misses by $0.16.Cash and cash equivalents of $264.99M.Press Release
Ra Pharmaceuticals Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Corporate Update
Ra Pharmaceuticals Announces Publication of Zilucoplan Phase 2 gMG Trial Results in JAMA Neurology
Ra Pharmaceuticals Announces Clearance of IND Application for the HEALEY ALS Platform Trial
Ra Pharmaceuticals Begins Phase II Study on Autoimmune Drug
Ra Pharmaceuticals (RARX) begins dosing of the first patient in its phase II study of zilucoplan for the treatment of immune-mediated necrotizing myopathy.
Ra Pharma commences mid-stage study of zilucoplan in rare type of myopathy
Dosing is underway in a 24-subject Phase 2 clinical trial evaluating Ra Pharmaceuticals' (NASDAQ:RARX) zilucoplan for the treatment of immune-mediated necrotizing myopathy, a rare type of idiopathic (
Ra Pharmaceuticals Announces Dosing of First Patient in Phase 2 Clinical Trial of Zilucoplan for IMNM
Ra Pharmaceuticals EPS misses by $0.05, beats on revenue
Ra Pharmaceuticals (NASDAQ:RARX): Q3 GAAP EPS of -$0.55 misses by $0.05.Revenue of $3M beats by $2.62M.Press Release
Ra Pharmaceuticals Reports Third Quarter 2019 Financial Results and Provides Corporate Update
Biotech stocks win October, rallying 8%
The biotechnology sector is up over 8% in October, lead by large-cap companies Biogen, Amgen and Celgene.